Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy

[thumbnail of Accepted Manuscript]
Preview
PDF (Accepted Manuscript) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
5MB

Item Type:Article
Title:Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
Creators Name:Nussstein, Hannah, Urbantat, Ruth M., Fentker, Kerstin, Loewe, Aditi, Duerr, Julia, Haji, Mohamed, Doellinger, Felix, Stahl, Mirjam, Graeber, Simon Y., Gradzielski, Michael, Röhmel, Jobst, Mertins, Philipp, Schaupp, Laura and Mall, Marcus A.
Abstract:BACKGROUND: Primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) are muco-obstructive lung diseases that are caused by distinct genetically determined defects in mucociliary clearance, however, knowledge on the relative severity of airway mucus dysfunction and chronic inflammation remains limited. The aim of this study was therefore to compare sputum viscoelastic properties, inflammation markers and the proteome between patients with PCD and patients with CF before and under elexacaftor/tezacaftor/ivacaftor (ETI) therapy. METHODS: We compared sputum rheology, inflammation markers and the proteome in 42 clinically stable adolescent and adult patients with PCD, 40 patients with CF with at least one F508del allele before (baseline) and 3 months after initiation of ETI and 15 age-matched healthy controls. RESULTS: The elastic modulus (G′) and viscous modulus (G″) of PCD sputum was increased compared to healthy controls (p<0.001), lower than in CF at baseline (p<0.001) and similar to CF on ETI. Inflammation markers in PCD sputum including neutrophil elastase (NE), free DNA, myeloperoxidase (MPO), interleukin (IL)-1β and IL-8 were also increased compared to healthy controls (all p<0.001), lower than in CF at baseline (p<0.05 to p<0.001) and comparable to CF on ETI. Similar, changes in the sputum proteome were less pronounced in PCD compared to CF at baseline, but comparable between PCD and CF on ETI. CONCLUSIONS: Clinically stable patients with PCD show changes in sputum viscoelastic properties, inflammation markers and the proteome that are less severe than in patients with CF at baseline, but comparable to CF patients on ETI therapy.
Keywords:Airway Inflammation, Cystic Fibrosis, Elexacaftor/Tezacaftor/Ivacaftor, Primary Ciliary Dyskinesia, Proteome, Sputum Rheology
Source:European Respiratory Journal
ISSN:0903-1936
Publisher:European Respiratory Society
Page Range:2500616
Date:18 September 2025
Official Publication:https://doi.org/10.1183/13993003.00616-2025
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library